Quantitative Hepatitis B Core Antibody Levels in the Natural History of Hepatitis B Virus Infection.

L. -W. Song,P. -G. Liu,C. -J. Liu,T. -Y. Zhang,X. -D. Cheng,H. -L. Wu,H. -C. Yang,X. -K. Hao,Q. Yuan,J. Zhang,J. -H. Kao,D. -S. Chen,P. -J. Chen,N. -S. Xia
DOI: https://doi.org/10.1016/j.cmi.2014.10.002
IF: 13.31
2015-01-01
Clinical Microbiology and Infection
Abstract:We previously demonstrated that pretreatment quantitative anti hepatitis B core protein (qAnti-HBc) levels can predict the treatment response for both interferon and nucleoside analogue therapy, but the characteristics of qAnti-HBc during chronic hepatitis B virus (HBV) infection remain poorly understood. To understand this issue, the qAnti-HBc levels were evaluated in individuals with past HBV infection, occult HBV infection and chronic HBV infection in the immune tolerance phase, immune clearance phase, low-replicative phase and hepatitis B e antigen (HBeAg)-negative hepatitis phase. Individuals with hepatitis B surface antigen (n = 598, 3.74 +/- 0.90 log(10) IU/mL) had significantly higher (p < 0.001, approximately 1000-fold) serum qAnti-HBc levels than those who had occult HBV, and serum qAnti-HBc levels were significantly higher in the occult HBV group than in the past HBV infection group (p < 0.001). qAnti-HBc levels were positively correlated with alanine aminotransferase levels (R = 0.663, p < 0.001), and subjects with an abnormal alanine aminotransferase level had a higher qAnti-HBc level (p < 0.001). Serum qAnti-HBc level varied in different phases of HBV infection, as determined by host immune status. Serum qAnti-HBc level is strongly associated with hepatitis activity in subjects with chronic HBV infection. Clinical Microbiology and Infection (C) 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
What problem does this paper attempt to address?